Skip to main content
Funded Studies

Daniel Otzen, PhD

Professor at University of Aarhus

Location: Denmark

Dr. Otzen was born in 1969 in Denmark but spent five years of his childhood in Malawi, Africa, where his father worked as a medical doctor. Dr. Otzen received his master’s degree in Chemistry and Molecular Biology at the University of Aarhus, Denmark in 1992 with the interactions between elongation factor Tu and transfer RNA as his thesis topic. He then spent the next two and a half years of his PhD studies under the supervision of Sir Alan Fersht at the University of Cambridge, studying protein stability and folding kinetics. After his degree (awarded December 1995 at the University of Aarhus), he was a staff scientist for two years at the Enzyme Division of the Danish pharmaceutical company Novo Nordisk, working on the stability and folding of industrial enzymes. Dr. Otzen returned to academia via a post-doctoral position focusing increasingly on protein aggregation at the University of Lund and was granted tenure as an Associate Professor at Aalborg University in 2000. Dr. Otzen’s research activities have since then focused on protein binding to membranes and protein aggregation, in particular the ability to prevent this aggregation for therapeutic and investigative purposes. After being promoted to full Professor in 2004, he accepted a professorship at University of Aarhus in 2007. He was an EMBO Young Investigator 2003-2006, was awarded the Silver Medal of the Danish Royal Society of Letters and Sciences in 2003 and received the Carlsberg Biotechnology Medal in 2006. Dr. Otzen has published around 100 articles in international peer-reviewed journals since 1993.


Associated Grants

  • From Anti-aggregation Assay to Treatment for Parkinson's Disease: Developing a Secondary Screen to Bridge High throughput Screen and Cellular Assay

    2009


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.